Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

July 31, 2025

Non-consolidated Financial Results for the Fiscal Year Ended June 30, 2025 (Under Japanese GAAP)

Company name: Temairazu, Inc.

Listing: Tokyo Stock Exchange

Securities code: 2477

URL: https://www.temairazu.co.jp/
Representative: Tetsuo Watanabe, President & CEO

Inquiries: Toshio Nakano, Director & Corporate Administration Department Manager

Telephone: +81-3-5447-6690

Scheduled date of annual general meeting of shareholders: September 24, 2025 Scheduled date to commence dividend payments: September 25, 2025 Scheduled date to file annual securities report: September 25, 2025

Preparation of supplementary material on financial results: Yes Holding of financial results briefing: Yes

(Yen amounts are rounded down to millions, unless otherwise noted.)

1. Non-consolidated financial results for the fiscal year ended June 30, 2025 (from July 1, 2024 to June 30, 2025)

(1) Non-consolidated operating results

(Percentages indicate year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Profit	
Fiscal year ended	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
June 30, 2025	2,185	8.0	1,608	8.9	1,620	9.6	1,067	9.3
June 30, 2024	2,023	11.9	1,476	10.9	1,479	10.9	976	11.7

	Basic earnings per share	Diluted earnings per share	Return on equity	Ratio of ordinary profit to total assets	Ratio of operating profit to net sales
Fiscal year ended	Yen	Yen	%	%	%
June 30, 2025	165.73	-	16.0	22.8	73.6
June 30, 2024	150.69	-	15.8	22.5	73.0

(2) Non-consolidated financial position

	Total assets	Net assets	Equity-to-asset ratio	Net assets per share
As of	Millions of yen	Millions of yen	%	Yen
June 30, 2025	7,218	6,768	93.8	1,077.93
June 30, 2024	6,977	6,557	94.0	1,012.01

Reference: Equity

As of June 30, 2025: ¥6,768 million As of June 30, 2024: ¥6,557 million

(3) Non-consolidated cash flows

	Cash flows from operating activities	Cash flows from investing activities	Cash flows from financing activities	Cash and cash equivalents at end of period
Fiscal year ended	Millions of yen	Millions of yen	Millions of yen	Millions of yen
June 30, 2025	1,056	-	-1,033	6,588
June 30, 2024	949	-6	-204	6,565

2. Cash dividends

	Annual dividends per share					Total cash		Ratio of
	First quarter-end	Second quarter-end	Third quarter-end	Fiscal year-end	Total	dividends (Total)	Payout ratio	dividends to net assets
	Yen	Yen	Yen	Yen	Yen	Millions of yen	%	%
Fiscal year ended June 30, 2024	-	14.00	-	20.00	34.00	220	22.6	3.6
Fiscal year ended June 30, 2025	-	15.00	-	23.00	38.00	241	22.9	3.6
Fiscal year ending June 30, 2026 (Forecast)	1	16.00	ı	24.00	40.00		22.7	

* Notes

- (1) Changes in accounting policies, changes in accounting estimates, and restatement
 - (i) Changes in accounting policies due to revisions to accounting standards and other regulations: None
 - (ii) Changes in accounting policies due to other reasons: None
 - (iii) Changes in accounting estimates: None
 - (iv) Restatement: None
- (2) Number of issued shares (common shares)
 - (i) Total number of issued shares at the end of the period (including treasury shares)

As of June 30, 2025	6,480,961 shares
As of June 30, 2024	6,480,396 shares

(ii) Number of treasury shares at the end of the period

As	s of June 30, 2025	201,879 shares
As	s of June 30, 2024	530 shares

(iii) Average number of shares outstanding during the period

Fiscal year ended June 30, 2025	6,440,768 shares
Fiscal year ended June 30, 2024	6,479,720 shares

^{*} Financial results reports are exempt from audit conducted by certified public accountants or an audit firm.

* Proper use of earnings forecasts, and other special matters

The forward-looking statements contained in this report are based on information currently available to the Company and certain assumptions which are regarded as legitimate. These statements are not promised by the Company regarding future performance. Actual results may differ significantly from these forecasts due to various factors.